(RFL) Rafael Holdings, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RFL) Rafael Holdings, Inc. Complete Analysis Pack
See the Bigger Picture
This Rafael Holdings, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy to show how it positions and sells its offerings; the page includes a genuine preview/sample of the analysis so you can evaluate format and insight before buying. Purchase the full version to get the complete ready-to-use report.
Product
2 business divisions
Rafael Holdings runs two business divisions: Pharmaceuticals and Real Estate. The mix pairs clinical-stage drug development with commercial property ownership, so the company has two separate value drivers. That split can balance long R&D cycles in Pharmaceuticals with steadier cash flow from real estate assets.
CPI-613 devimistat
CPI-613, or devimistat, is Rafael Holdings, Inc.'s flagship drug candidate and lead pharmaceutical asset. It targets metabolic differences between healthy cells and malignant cells, aiming to weaken cancer cell energy use. As a clinical-stage asset, its value sits in pipeline upside rather than revenue, so it is the core product shaping Rafael Holdings, Inc.'s pharma mix.
2 Phase III trials
CPI-613 is in 2 pivotal Phase III registrational studies, one in advanced pancreatic cancer and one in relapsed/refractory acute myeloid leukemia. These are Rafael Holdings, Inc.’s most advanced pipeline assets, and Phase III trials are the last major step before a potential regulatory filing.
Office complex and parking
Rafael Holdings, Inc. uses its office complex and 800-space public parking facility as income-producing real estate, with rent and parking fees tied to the same site. The office asset is the core of the Real Estate segment, so cash flow depends on occupancy, tenant demand, and garage use.
This setup adds one clear edge: tenants and visitors get on-site parking, which supports leasing appeal and steadier income.
- Commercial office complex
- Integrated 800-space public garage
- Income-producing real estate asset
Metabolic-targeted therapies
Rafael Holdings, Inc. positions metabolic-targeted therapies as a science-led product concept that attacks the altered energy use of cancer cells, not just one drug. The pipeline is still clinical-stage, with no approved oncology product and no reported product revenue in the latest public filings. This makes the product story about platform biology, not a single asset.
- Targets cancer metabolism
- Clinical-stage, no approvals
- Pipeline-driven product logic
Rafael’s CPI-613 Advances in Two Phase III Cancer Trials
Rafael Holdings, Inc.'s product is a clinical-stage oncology pipeline led by CPI-613, or devimistat, a metabolic-targeted cancer therapy. In the latest public filings, the product side had no approved oncology drug and no reported product revenue. CPI-613 is in 2 Phase III registrational studies, one in pancreatic cancer and one in relapsed/refractory AML.
| Product | 2025/2026 status | Key data |
|---|---|---|
| CPI-613 | Clinical stage | 2 Phase III trials; no product revenue |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific breakdown of Rafael Holdings, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Summarizes Rafael Holdings’ 4Ps in one clear view, making strategy gaps easy to spot and discuss fast.
Reference Sources
Provides a concise, traceable sources list linking each key claim to industry reports, government data, and benchmarks to speed due diligence and boost credibility.
Place
Newark HQ
Rafael Holdings, Inc. keeps its corporate headquarters in Newark, New Jersey, which serves as the company’s main base for management and reporting. The Newark HQ anchors both operating divisions, so it is the control center for strategy, finance, and oversight. In 2025/2026 terms, that makes one location responsible for coordinating 2 divisions and the company’s public-market disclosures.
U.S. assets
Rafael Holdings, Inc. keeps its real estate footprint in the United States, where commercial properties support leasing income and day-to-day property management. This U.S. base is the core market for the segment, so occupancy, rent rolls, and tenant retention matter most here. U.S. commercial real estate still anchors the portfolio’s cash flow and operating focus.
Israel assets
Rafael Holdings’ Israel real estate assets give the company a 2-country footprint, with operations tied to both the U.S. and Israel in FY2025. That cross-border base supports the Place strategy by widening access to assets, tenants, and local market opportunities. It also adds geographic diversification, which can help reduce reliance on one market.
Office leasing channel
Rafael Holdings, Inc. uses the Real Estate segment’s office leasing channel to make the office complex available through commercial lease contracts. The site’s 800-space parking facility supports easier tenant access and daily use, which helps leasing appeal.
In the latest public filings, this channel remains tied to the segment’s rental-income model, where occupancy and lease terms drive cash flow. The 800-space lot is a clear site-level advantage for tenants and visitors.
- Commercial lease contracts drive access
- Real Estate segment supplies office space
- 800 parking spaces improve accessibility
Clinical trial network
Rafael Holdings, Inc. relies on a multi-site clinical trial network to place CPI-613 in front of eligible patients and research partners. This "place" channel is critical because the drug can only be tested and monitored where investigators and trial patients are already connected. In 2025, network reach matters as much as lab data, since enrollment speed and site quality drive study progress.
- Multi-site access speeds patient enrollment
- Sites handle CPI-613 testing and monitoring
- Research partners expand trial reach
- Network quality affects study timelines
Rafael Holdings Centers Strategy in Newark with U.S.-Israel Reach
Rafael Holdings, Inc.’s Place strategy is anchored in Newark, New Jersey, which serves as the corporate control point for 2 operating divisions. Its real estate footprint stays centered in the U.S., with Israel adding a 2-country base in FY2025. The office-leasing site’s 800-space parking facility improves tenant access and daily use. For CPI-613, a multi-site trial network places the drug at eligible research sites.
| Place lever | Latest data |
|---|---|
| HQ | Newark, New Jersey |
| Geography | U.S. and Israel |
| Parking | 800 spaces |
| Operating divisions | 2 |
Get Your Copy
Rafael Holdings, Inc. Reference Sources
The preview shown here is the actual Rafael Holdings, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use with product, price, place, and promotion insights.
Promotion
SEC filings
Rafael Holdings uses SEC filings, especially its Form 10-K and Form 10-Q, as a core promotion channel for investors. These filings show revenue, net loss, cash, assets, and business updates, so they shape how the market reads the Company Name’s story. For a public company, this is the most direct and credible way to promote transparency.
Earnings releases
Rafael Holdings, Inc. uses quarterly and annual earnings releases to keep the market updated on its 2025 fiscal-year results. The releases break out performance across its 2 core segments, pharmaceuticals and real estate, so shareholders can track operating progress in each line. This steady disclosure helps investors compare quarter to quarter and see where value is changing.
Trial updates
Clinical trial updates are a key promo tool for Rafael Holdings, Inc.'s pharmaceutical arm, because Phase III milestones on CPI-613 show late-stage progress. In fiscal 2025, the value signal came from development news, not product sales, so each update mattered to doctors and investors. Clear enrollment, endpoint, and timing updates keep CPI-613 visible and credible.
Investor presentations
Investor presentations help Rafael Holdings explain its strategy and 2-part portfolio: life sciences and real estate. They make the dual-business model easier to follow for current and potential investors, and they frame capital use, risk, and growth priorities in one place.
- Clear view of 2 business lines
- Supports investor communication
- Shows strategy and portfolio mix
Leasing outreach
Rafael Holdings, Inc. uses leasing outreach to market available office space, fill vacancies, and support lease renewals in its Real Estate segment. This is the property business’s main commercial promotion channel, and it directly affects occupancy, rent roll stability, and cash flow.
In fiscal 2025, that matters because every renewed lease helps protect recurring rental income and lowers downtime risk between tenants.
- Targets office tenants
- Supports occupancy
- Drives lease renewals
- Protects rental cash flow
Rafael Holdings Uses Filings, Clinical Updates, and Leasing to Build Trust
Rafael Holdings, Inc. promotes itself mainly through SEC filings, earnings releases, and investor decks that explain its 2 segments: pharmaceuticals and real estate. In fiscal 2025, clinical updates on CPI-613 and leasing outreach were the most visible market-facing tools. These channels support transparency, tenant demand, and investor confidence.
| Channel | FY2025 use | Impact |
|---|---|---|
| SEC filings | 10-K and 10-Q | Investor transparency |
| Clinical updates | CPI-613 Phase III | Pipeline visibility |
| Leasing outreach | Office tenants | Occupancy and rent flow |
Price
Negotiated lease rents
Rafael Holdings, Inc. sets negotiated lease rents through commercial contracts, so price moves with demand, location, and building features. Its 800-space parking facility adds real tenant value by improving access and convenience, which can support stronger lease terms. In tight markets, better access and usable amenities often help landlords defend rent levels.
Public equity valuation
Rafael Holdings, Inc.’s public equity price is the clearest price signal for the holding company, because its value is set by the market every trading day. That share price moves with investor views on its pharmaceuticals pipeline and real estate assets, so news on either can shift valuation fast. In practice, the stock price is the main market-based measure of Company Name’s worth.
Capital raises
Rafael Holdings, Inc. can fund development and operations with equity or other capital-market raises, but the deal price drives dilution and cash runway. For a holding company, financing cost is part of the price strategy, so a raise priced too low can hurt per-share value even if it boosts liquidity. The key trade-off is simple: cheaper capital helps cash, but it can cost owners more.
Clinical-stage economics
CPI-613 is still in clinical development, so Rafael Holdings, Inc. does not set a consumer sale price for it. Its value is tied to trial outcomes, FDA progress, and partner deals, so economics are milestone-based, not retail-based.
- Clinical-stage, not commercial.
- Value rises with trial success.
- Pricing comes from milestones and licensing.
No consumer list price
Rafael Holdings does not sell a consumer product, so there is no public shelf price for end buyers. Its pharmaceutical asset is not shown here as an approved, marketed medicine, which means pricing is still tied to R&D and partnering, not retail demand. In fiscal 2025, that keeps Price at zero for consumers, with no listed MSRP or copay data.
- No consumer list price
- Not a retail goods model
- Pharma asset not marketed here
- Price depends on future approval
Rafael Holdings: No List Price, Just Lease Value and Market Signals
Rafael Holdings, Inc. has no consumer list price in fiscal 2025 because CPI-613 is still clinical-stage, not marketed. Its "price" is set by lease rents, equity trading, and capital-raise terms, with the 800-space parking asset helping support stronger lease pricing. For investors, the stock price is the main market signal of value.
| Price Item | FY2025 |
|---|---|
| Consumer list price | N/A |
| Parking spaces | 800 |
| CPI-613 status | Clinical-stage |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.